Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Personalis (NASDAQ:PSNL) announced its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06), FiscalAI reports. Personalis had a negative return on equity of 45.98% and a negative net margin of 148.11%.The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million.

Here are the key takeaways from Personalis’ conference call:

• Personalis reported strong clinical volume momentum with 7,800 NeXT Personal tests in Q1 (26% sequential, 258% YoY), surpassed >1,000 ordering physicians in the quarter, and reconfirmed a 2026 clinical volume target of 43,000–45,000 tests.
• Q1 revenue was $15.5M (down ~25% YoY) and gross margin compressed to 1.8% due to unreimbursed scaling; net loss widened to $30M and full-year net loss is guided to about $105M with ~$100M expected cash usage despite a $233M cash balance.
• Reimbursement and clinical evidence progress: Medicare coverage for breast and lung surveillance is live, MolDX submissions are pending for neoadjuvant breast and pan‑cancer IO, and presented data (NEOPRISM‑CRC, DARWIN‑2, 10k real‑world cohort) highlighted high negative predictive value and the value of ultrasensitivity.
• Biopharma MRD momentum and backlog are growing: Q1 biopharma MRD revenue was $3.1M with management targeting $20M–$21M for the full year, expecting most MRD revenue to ramp in H2 as several large trials commence.

Personalis Stock Down 0.2%

PSNL stock traded down $0.01 during trading on Friday, hitting $5.98. The company had a trading volume of 2,726,536 shares, compared to its average volume of 2,046,896. The firm has a market capitalization of $625.99 million, a P/E ratio of -5.86 and a beta of 1.96. Personalis has a 52-week low of $3.84 and a 52-week high of $11.50. The company has a 50 day simple moving average of $6.93 and a 200-day simple moving average of $8.23.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday. Guggenheim increased their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research raised their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its stake in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after buying an additional 1,655 shares during the period. Royal Bank of Canada increased its stake in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares during the period. Howland Capital Management LLC increased its stake in Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after buying an additional 2,500 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after buying an additional 3,592 shares during the period. Finally, Intech Investment Management LLC increased its stake in Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after buying an additional 3,851 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.